Development Information. Sankyo shall keep MTI informed as to the progress of Sankyo in the development and testing of all Licensed Compounds and Products and the preparing, filing and obtaining of the approvals necessary for marketing. In addition, Sankyo shall provide MTI with a minimum of three (3) months' advance notice of the contemplated filing of an IND or an NDA. Sankyo shall also provide MTI with a report on all regulatory submissions, communications or meetings on or prior to the date of such submissions and a copy of any INDs, NDAs or other regulatory communication within five (5) days of filing thereof, which material shall be subject to Article 11 hereof except as otherwise set forth herein.
Appears in 2 contracts
Sources: Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc), Collaborative Research and Development and License Agreement (Metabasis Therapeutics Inc)